Expert NetworkExpert InterviewKPTI

Slingshot members are talking to an expert! The topic is:

A Second Look: Exploring the Potential of Selinexor and Ruxolitinib in Myelofibrosis from Karyopharm Therapeutics' Phase 3 SENTRY Trial

Executed on:Apr 21, 2026 12:30 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: University of Utah Health and Huntsman Cancer Institute
  • Associate Professor of Medicine (Hematology) and Hematologic Malignancy Specialist at Huntsman Cancer Institute; Board-certified in Hematology and Medical Oncology
  • Treats 100 patients with myelofibrosis per year within a major academic cancer center
  • Specializes in hematologic malignancies including acute and chronic leukemias, myelofibrosis, and myelodysplastic syndromes, with a strong focus on genetic predisposition and telomere biology disorders; actively leads and participates in innovative clinical trials evaluating novel therapies for myeloid cancers, and contributes to national research efforts and peer-reviewed publications advancing treatment of bone marrow failure and leukemia

Interview Goal

To gain a deeper understanding of Selinexor (XPO1 inhibitor; marketed as XPOVIO®) in Combination with Ruxolitinib for Myelofibrosis

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.